Determination of Stiripentol in Plasma by High-performance Liquid Chromatography with Fluorescence Detection

DOI Web Site 12 References
  • Takahashi Ryohei
    Department of Clinical Trials Office, Saitama Cancer Center Department of Drug Metabolism and Disposition, Meiji Pharmaceutical University
  • Imai Koichi
    Saitama Prefectural Institute of Public Health
  • Yamamoto Yoshiaki
    Department of Clinical Research, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders
  • Takahashi Yukitoshi
    Department of Clinical Research, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders
  • Hamano Shin-ichiro
    Division of Neurology, Saitama Children's Medical Center
  • Yoshida Hisahiro
    Department of Drug Metabolism and Disposition, Meiji Pharmaceutical University

Search this article

Abstract

<p>We herein developed a method that required a smaller sample volume to rapidly determine plasma stiripentol (STP) concentrations in patients with Dravet syndrome by means of reverse-phase high-performance liquid chromatography (HPLC) using a fluorescence detector (Ex/Em: 210/400 nm). A pretreatment involved simple deproteinization with acetonitrile. A Discovery® HS C18 column, 3 μm, 4.6 mm × 150 mm was used for isolation by HPLC. The mobile phase, consisting of 25 mM phosphate buffer (pH 2.6) and acetonitrile (43:57, v/v), had a flow rate of 1.5 mL/min. The retention time was 4.6 minutes, and the lower limit of quantification was 0.05 μg/mL. Specificity testing revealed no influence on the peak. A plasma sample of 10 μL was sufficient to measure plasma STP concentrations in patients with Dravet syndrome; thus, the burden on these patients was markedly reduced. These results suggest that the determination of plasma STP concentrations was useful.</p>

Journal

References(12)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top